식도암의 치료, 어디까지 와 있는가?

Over the decades, the treatment of the esophageal cancer has been debated. Multimodal therapy is a important keystone in advanced esophageal cancer. Neoadjuvant chemoradiation therapy is now known to provide advantages for treating stage II and stage III esophageal squamous cell cancer and can also...

Full description

Saved in:
Bibliographic Details
Published inJournal of digestive cancer reports Vol. 1; no. 1; pp. 17 - 23
Main Authors 전준한, 정대영, Joon Han Jeon, Dae Young Cheung
Format Journal Article
LanguageKorean
Published 2013
Online AccessGet full text

Cover

Loading…
More Information
Summary:Over the decades, the treatment of the esophageal cancer has been debated. Multimodal therapy is a important keystone in advanced esophageal cancer. Neoadjuvant chemoradiation therapy is now known to provide advantages for treating stage II and stage III esophageal squamous cell cancer and can also be considered for the esophageal adenocarcinoma. Definitive chemoradiation therapy results in long-term survival compared with surgery alone. This review aims to provide recent consensus recommendations based on the data and literatures. 식도암의 치료는 근치적 절제와 화항방사선치료를 포함하는 다중치료가 보편적으로 받아들여지고 있다. 그러나 치료의 종양학적 결과는 충분히 만족스러운 수준에 이르고 있지 못하다. 이에 대하여 기존 항암 화학요법과 방사선치료, 수술 그리고 표적약물의 적용에 대한 연구가 지속되고 있다. 이 논문에서는 문헌과 보고를 근거로 식도암 치료에 대한 최근의 합의과 권고를 정리하였다.
Bibliography:KISTI1.1003/JNL.JAKO201320872000506
ISSN:2288-1581
2765-6713